Web2 dic 2024 · Celgene’s focus seems to have switched back to its multiple myeloma comfort zone, and at Ash it played up its BCMA-targeting assets, with the emphasis on JCAR017 shifting to chronic lymphoblastic leukaemia (CLL). Transcend-NHL – the JCAR017 lymphoma study that Juno had called registrational – was relegated to a low-key poster. Web16 nov 2024 · This is an open-label, multicenter, Phase 2 study to determine the safety, PK, and efficacy of lisocabtagene maraleucel (JCAR017) in subjects who have relapsed from, or are refractory to, two lines of immunochemotherapy for aggressive B-cell non-Hodgkin lymphoma (NHL) in the outpatient setting.
BMS files first drug from triple bet with Celgene ... - pharmaphorum
Web21 dic 2016 · The FDA granted breakthrough therapy designation for JCAR017 – a CD19-targeted chimeric antigen receptor (CAR) T-cell therapy – for patients with relapsed/refractory, aggressive large B-cell non-Hodgkin lymphoma (NHL), specifically those with diffuse large B-cell lymphoma (DLBCL), primary mediastinal B-cell lymphoma, grade … Web22 mar 2024 · Based on these findings, Bristol-Myers Squibb recently submitted the product JCAR017 (international nonproprietary name Lisocabtagene maraleucel; market name Breyanzi (R) lab code liso-cel) for ... expertbook b1 b1400ceae-ek5015r
A Study to Compare the Effectiveness and Safety of JCAR017 to …
Web7 dic 2024 · JCAR017 is a CD19-directed 4-1BB CAR T cell product with a highly controlled manufacturing process that enables administration in a defined composition at a precise … Web11 dic 2015 · La dose e il programma di JCAR017 saranno valutati e modificati, se necessario, per la sicurezza e l'attività antitumorale. Stabiliremo anche per quanto tempo le cellule T modificate rimangono nel corpo del paziente e quanto bene JCAR017 funziona nel trattamento di pazienti con linfoma non Hodgkin la cui malattia è ricomparsa o non ha … Web2 lug 2024 · This is a randomized, open-label, parallel-group, multi-center trial in adult subjects with Relapsed or refractory (R/R) aggressive Non-Hodgkin lymphoma (NHL) to … expertbook l1400cda-ek0477